| SPEAKER - Davide Corti |
|
|
Davide Corti Chief Scientific Officer, Humabs BioMed SA, Bellinzona, Switzerland |
|
Dr. Davide Corti (PhD) obtained his bachelor in Pharmaceutical Biotechnology at the University of Milan and his PhD in Immunology at the University of Bern, followed by postdoctoral training in the Antonio Lanzavecchia’s laboratory at the Institute for Research in Biomedicine where he further developed and optimized two methods for the isolation of human monoclonal antibodies out of memory B cells and plasma cells (Cellclone technologies). Since 2009 he is the Chief Scientific Officer at Humabs, where he leads a research group to isolate monoclonal antibodies against multiple infectious disease agents. Starting from 2012 he has collaborated extensively with MedImmune on the isolation of human antibodies against multiple target pathogens like Rhinovirus, Influenza B, Klebsiella and Staphylococcus. His team’s efforts to date have generated two clinical candidates, MEDI8852 targeting Influenza A and anti-CMV antibodies currently in Phase 2 studies. Dr. Corti has published 52 peer reviewed journal articles and held nine patents. |
|
